Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Takayama

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
BMC Urology|July 9, 2025
Preoperative CRP is a predictive factor for prolonged hospital stay after radical cystectomy for bladder cancerTakuji Hayashi, Atsunari Kawashima, Takeshi Ujike, et al.
Cancer Treatment and Research Communications|May 29, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinomaYujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Journal of Radiation Research|October 24, 2015
Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapyHiromichi Ishiyama, Takefumi Satoh, Atsunori Yorozu, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
BMC Urology|July 9, 2025
Preoperative CRP is a predictive factor for prolonged hospital stay after radical cystectomy for bladder cancerTakuji Hayashi, Atsunari Kawashima, Takeshi Ujike, et al.
Cancer Treatment and Research Communications|May 29, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinomaYujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Journal of Radiation Research|October 24, 2015
Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapyHiromichi Ishiyama, Takefumi Satoh, Atsunori Yorozu, et al.
Pageof 7